Analysis

Friedman Industries, Incorporated Announces Second Quarter Results and Provides Near-term Outlook

Retrieved on: 
Friday, December 2, 2022

Inventory tons sold increased from approximately 43,000 tons in the 2021 quarter to approximately 106,500 tons in the 2022 quarter.

Key Points: 
  • Inventory tons sold increased from approximately 43,000 tons in the 2021 quarter to approximately 106,500 tons in the 2022 quarter.
  • Tubular segment sales for the 2022 quarter totaled $19,970,196 compared to $14,246,968 for the 2021 quarter.
  • The tubular segment recorded operating profits of approximately $3,341,000 and $1,997,000 for the 2022 quarter and 2021 quarter, respectively.
  • The third quarter volume expectation is slightly lower than the second quarter volume due primarily to the impact of holidays during the third quarter of fiscal 2023.

Valvoline Establishes ESG and Equality Council to Support Continued Progress on Sustainabilty, DE&I and Governance Matters

Retrieved on: 
Friday, December 2, 2022

The Council will be overseen by Valvolines Board of Directors through its Governance & Nominating Committee, and led by Julie ODaniel, Senior Vice President, Chief Legal Officer and Corporate Secretary of Valvoline.

Key Points: 
  • The Council will be overseen by Valvolines Board of Directors through its Governance & Nominating Committee, and led by Julie ODaniel, Senior Vice President, Chief Legal Officer and Corporate Secretary of Valvoline.
  • Valvoline director Carol H. Kruse, the former Senior Vice President and Chief Marketing Officer at ESPN and Cambia Health Solutions, will be joining the Council, as will other senior executives of Valvoline.
  • The Council will enhance these initiatives with corporate governance practices and will work closely with Valvolines employee-driven DEI Council to deepen the Companys commitment to an inclusive culture for all.
  • "We are pleased that Valvoline has formed this goal-oriented and disclosure-focused Council to engender a more inclusive workplace.

Goodfood Achieves Significant Gross Margin Expansion, Improves Adjusted EBITDA(1) by 89% Year-over-Year and Reaffirms Expectation of Positive Adjusted EBITDA(1) in First Half of FY2023

Retrieved on: 
Friday, December 2, 2022

Goodfoods core purpose is to create experiences that spark joy and help our community live longer on a healthier planet.

Key Points: 
  • Goodfoods core purpose is to create experiences that spark joy and help our community live longer on a healthier planet.
  • As a result, we are reconfirming our expected path to return to positive quarterly Adjusted EBITDA1 in the first half of 2023 with continued growth thereafter.
  • Adjusted gross margin is defined as the percentage of adjusted gross profit to net sales.
  • EBITDA, Adjusted EBITDA & Adjusted EBITDA margin: EBITDA is defined as net income or loss before net finance costs, depreciation and amortization and income taxes.

NUROSENE BUSINESS UPDATE

Retrieved on: 
Thursday, December 1, 2022

TORONTO, Dec. 1, 2022 /PRNewswire/ - Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF), a company that is focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the pharmaceutical industry, is pleased to share the following business update.

Key Points: 
  • TORONTO, Dec. 1, 2022 /PRNewswire/ - Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF), a company that is focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the pharmaceutical industry, is pleased to share the following business update.
  • The opportunity At Nurosene, we believe there is a significant opportunity to address the very low rate of success in the clinical trial process, by using the NetraAI technology.
  • Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
  • New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors.

Global Liquid Biopsy Market Report to 2027: Featuring Abbott Laboratories, AccuraGen, BGI Genomics and Biocartis Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022

Including Executive and Consultant Guides and Customized Forecasting and Analysis 2023-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Including Executive and Consultant Guides and Customized Forecasting and Analysis 2023-2027" report has been added to ResearchAndMarkets.com's offering.
  • The Screening, Diagnostic, Therapy Selection, Recurrence Monitoring and Screening Market Potential are all explored in this report.
  • What is the impact of the COVID pandemic on the Liquid Biopsy market?
  • New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures.

UJET Connect Provides Seamless Cloud Migration for Contact Center Customers of Legacy On-Premises Providers

Retrieved on: 
Thursday, December 1, 2022

UJET, Inc. , the worlds most advanced contact center platform, today announced UJET Connect , a new option for customers to easily expedite their transition to the UJET cloud platform.

Key Points: 
  • UJET, Inc. , the worlds most advanced contact center platform, today announced UJET Connect , a new option for customers to easily expedite their transition to the UJET cloud platform.
  • Service consistency and business continuity for the contact center is fundamental to the success of every company, and UJET Connect ensures a fast, easy, and uninterrupted transition to the cloud for new UJET customers.
  • UJET Connect is a program that offers a phased roadmap and blueprint to contact center transformation with a seamless migration process from legacy platforms, including hybrid and on-premises systems.
  • With modern solutions backed by the progressive capabilities of the cloud, customer service providers are future-proofing their operations with UJET, the worlds most advanced contact center.

Guardant Health to Showcase New Data at San Antonio Breast Cancer Symposium 2022 Demonstrating Utility of Its Blood Tests for Advanced-stage Breast Cancer Patients

Retrieved on: 
Thursday, December 1, 2022

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the 2022 San Antonio Breast Cancer Symposium, December 6-10 in San Antonio, Texas.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the 2022 San Antonio Breast Cancer Symposium, December 6-10 in San Antonio, Texas.
  • We look forward to sharing new data at the San Antonio Breast Cancer Symposium demonstrating the utility of our blood tests to increase the understanding of potential biomarker targets and the mechanisms of molecular response in patients with advanced breast cancer, said Helmy Eltoukhy, Guardant Health co-CEO.
  • Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics.
  • Guardant Health has commercially launched Guardant360, Guardant360 CDx, Guardant360 TissueNext, Guardant360 Response, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal for early-stage cancer patients.

SAIC Named a Company to Watch in Frost & Sullivan Joint All Domain Command and Control Report

Retrieved on: 
Thursday, December 1, 2022

Science Applications International Corp. (NYSE: SAIC ) has been recognized by Frost & Sullivan as a company to watch, supporting Department of Defense (DoD) Joint All-Domain Command and Control (JADC2).

Key Points: 
  • Science Applications International Corp. (NYSE: SAIC ) has been recognized by Frost & Sullivan as a company to watch, supporting Department of Defense (DoD) Joint All-Domain Command and Control (JADC2).
  • This recognition demonstrates SAICs role as a transformation agent in JADC2 as we continue to contribute to the success of our nations warfighters.
  • SAIC is one of only three companies Frost & Sullivan named as a JADC2 Company To Watch, said Brad Curran, aerospace and defense principal analyst at Frost & Sullivan.
  • SAIC also disclaims any duty to comment upon or correct information that may be contained in reports published by investment analysts or others.

Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA

Retrieved on: 
Thursday, December 1, 2022

ADX-2191, which has received FDA Orphan Drug Designation for the treatment of primary vitreoretinal lymphoma, is a novel, vitreous-compatible formulation of methotrexate.

Key Points: 
  • ADX-2191, which has received FDA Orphan Drug Designation for the treatment of primary vitreoretinal lymphoma, is a novel, vitreous-compatible formulation of methotrexate.
  • ADX-2191 has received FDA Orphan Drug Designation for the prevention of proliferative vitreoretinopathy, and the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
  • Primary vitreoretinal lymphoma is a rare, aggressive, and potentially fatal retinal cancer that is diagnosed in approximately 300 to 600 patients in the United States per year.
  • Data on file; Primary Vitreoretinal Lymphoma by D. J. Wilson on AAO EyeWiki; M. Sagoo, Survey of Ophthalmology (2014); Grimm et.

Mission Accomplished: Canoo Delivers Light Tactical Vehicle to Army for Analysis & Demonstration

Retrieved on: 
Thursday, December 1, 2022

JUSTIN, Texas, Dec. 1, 2022 /PRNewswire/ -- Canoo (NASDAQ: GOEV), a leading high-tech advanced mobility company, has delivered its new Light Tactical Vehicle (LTV) to the United States Army for Analysis & Demonstration in fulfilment of the contract awarded in July 2022.

Key Points: 
  • "The LTV is another milestone proving the power of our technology," said Tony Aquila, Chairman & CEO at Canoo.
  • As with all Canoo vehicles, the LTV is designed for passenger ergonomics, taking body motion and height into consideration as well as multi-taskcomponents.
  • "The LTV is another milestone proving the power of our technology and how it can be used, even in tactical situations," said Tony Aquila, Chairman & CEO at Canoo.
  • Modular for Multiple Use Cases: Convertible Flatbed, Mounting Racks, Ramps & Tactical Systems
    A jack-of-all trades, the Light Tactical Vehicle can be converted from a pickup to a flatbed truck, a cargo vehicle and more.